1. Medicines
  2. Rheumatology
  3. COSENTYX® (secukinumab)

Click here for Prescribing Information

Cosentyx (secukinumab)

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Cosentyx (secukinumab) in Rheumatology

Cosentyx is the first and only fully human targeted IL-17A inhibitor that offers fast and lasting relief from the signs and symptoms of PsA* and axSpA†‡

Cosentyx_WhyCosentyx_HCP_1

 

Cosentyx_WhyCosentyx_HCP_2

 

Cosentyx_WhyCosentyx_HCP_3

 

Find out more using the links below...

Arrow with the text: Why Cosentyx in PsA? Click image to find out more

Arrow with the text: Why Cosentyx in axSpA? Click image to find out mor

Arrow with the text: Can targeting IL-17A make the difference? Click image to find out more*

*Patients with PsA receiving Cosentyx achieved significant improvement in ACR20 vs placebo at Week 24: 54% Cosentyx300 mg s.c.; 51% 150 mg s.c. vs 15% placebo P<0.0001.2 This improvement was sustained after 5 years of treatment.3
†Patients with AS receiving Cosentyx achieved significant improvement in ASAS20 vs placebo at Week 16: 61% Cosentyx 150 mg s.c. vs 28% placebo (P<0.001).5 This improvement was sustained after 5 years of treatment.6
‡Patients (NSAID-IR) with nr-axSpA receiving Cosentyx 150 mg s.c. vs placebo (N=555). Primary endpoint was met: ASAS40 at Week 16 and Week 52. ASAS40 vs placebo at Week 16: 42% Cosentyx 150 mg s.c. vs 29% placebo (P<0.05). This improvement was sustained after 1 year of treatment.7
δPatients with active AS receiving Cosentyx 150 mg (n=54 at Year 5).6
§Not limited to licensed indications.
**Across all licensed indications.

ACR, American College of Rheumatology; AS, ankylosing spondylitis; ASAS, Assessment in SpondyloArthritis international Society; axSpA, axial spondyloarthritis; BAD, British Association of Dermatologists; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism IL, interleukin; ISR, injection site reaction; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis; s.c. subcutaneous; TB, tuberculosis.

  1. Cosentyx SmPC Available at www.medicines.ie last accessed March 2023
  2. McInnes IB et al. Lancet. 2015;386:1137–46.
  3. McInnes IB et al. Lancet Rheumatol. 2020;2:e227–35.
  4. Rheumatology DOF UK 102.
  5. Baeten D et al. N Engl J Med. 2015;373:2534–48.
  6. Marzo-Ortega H et al. Lancet Rheumatology. 2020;2:e339–46.
  7. Deodhar A et al. Arthritis Rheumatol. 2020 (epub ahead of print).
  8. Reich K et al. Br J Dermatol. 2019;181:954–66.
  9. Thaci D et al. J Am Acad Dermatol. 2015;73:400–9.
  10. Baraliakos X et al. Ann Rheum Dis. 2019;78. Abstract OP0235.
  11. McInnes IB et al. Lancet Rheumatol. 2020;2(4):e227-e235
  12. Baraliakos X et al. RMD Open. 2019;5(2):e001005.
  13. Braun J et al. Rheumatology (Oxford). 2019;58:859–68.
  14. Deodhar A et al. Ann Rheum Dis. 2020;79:722.
  15. Langley RG et al. N Engl J Med. 2014;371:326–38.
  16. McInnes IB et al. Lancet 2020;395:1496–505.
  17. Yiu Z et al. Br J Dermatol. 2020;183:294–302.
  18. Novartis Data on File. Secukinumab Cumulative Patient Numbers, Sec008. Feb 2023
  19. ClinicalTrials.gov. A study comparing AIN457 to placebo in subjects with a diagnosis of moderate to severe stable plaque psoriasis. https://clinicaltrials.gov/ct2/show/NCT00669916. Accessed 20 March 2023.
  20. Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis [press release]. Basel, Switzerland. 17 September 2019. Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis | Novartis Accessed 23 March 2023
  21. Novartis Q1 2022 Earnings. Available at: Q1 2022 Results (novartis.com) Accessed April 2022.
Rate this content: 
No votes yet
IE271483 | March 2023
Rheumatology
Medicines
Print

Reporting of side effects
Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.

×

Ask Speakers

×

Medical Information Request